UNSPSC 51152200: Combination neuromuscular blocking agents

This classification denotes combination drugs and preparations that interrupt transmission of nerve impulses at the skeletal neuromuscular junction and which therefore bear the name NEUROMUSCULAR BLOCKING AGENTS. Typical combination neuromuscular blocking agent constituents are mivacurium chloride and dextrose.

UNSPSC 51152200 Combination neuromuscular blocking agents is a Class code that shows minimal recent relevance to state and local procurement activity. The two recent opportunities tagged under this code diverge significantly from the nominal scope: Seminole County, Florida's IFB for naloxone and drug deactivation systems, and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs address pharmaceutical procurement and public health supply chains rather than combination neuromuscular blocking agents used in anesthesia and critical care. The mismatch suggests either miscoding by the issuing bodies or a data alignment issue rather than active state and local demand for the product category the code nominally describes.

State and local procurement activity under this code appears sparse at the class level. Issuing bodies include county health departments and state health agencies, but the recent record does not support characterizing a repeating buyer base or geographic concentration. The Seminole County opportunity (IFB60459723LAS, due July 26, 2023) and the Texas HHS RFI (HHS0017013, posted April 3, 2026) are isolated instances rather than indicators of sustained market activity. Given the divergence between the code's pharmacological definition and the actual products being solicited, pursuit under this specific code is not recommended without clarification of whether issuing bodies are using it correctly or whether they intend different pharmaceutical supply categories.